IN2014DN08675A - - Google Patents

Info

Publication number
IN2014DN08675A
IN2014DN08675A IN8675DEN2014A IN2014DN08675A IN 2014DN08675 A IN2014DN08675 A IN 2014DN08675A IN 8675DEN2014 A IN8675DEN2014 A IN 8675DEN2014A IN 2014DN08675 A IN2014DN08675 A IN 2014DN08675A
Authority
IN
India
Prior art keywords
fusion protein
rmyc
recombinant
ag85b
hbha
Prior art date
Application number
Inventor
John Fulkerson
Michael Brennan
Kamalakannan Vlemurugan
Camille Locht
Original Assignee
Aeras Global Tb Vaccine Found
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeras Global Tb Vaccine Found, Inst Nat Sante Rech Med filed Critical Aeras Global Tb Vaccine Found
Publication of IN2014DN08675A publication Critical patent/IN2014DN08675A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Abstract

Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin binding hemagglutinin (HBHA) fusion protein are provided as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc is post translationally methylated and is highly antigenic.
IN8675DEN2014 2012-04-16 2012-04-16 IN2014DN08675A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/033757 WO2013158061A1 (en) 2012-04-16 2012-04-16 Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN08675A true IN2014DN08675A (en) 2015-05-22

Family

ID=49383839

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8675DEN2014 IN2014DN08675A (en) 2012-04-16 2012-04-16

Country Status (6)

Country Link
US (2) US9926346B2 (en)
EP (1) EP2838990A4 (en)
JP (1) JP2015515276A (en)
CN (1) CN104508120A (en)
IN (1) IN2014DN08675A (en)
WO (1) WO2013158061A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144139A1 (en) * 2018-01-22 2019-07-25 Oregon State University Immunogenic compositions comprising mycobacterium bovis surface proteins and uses thereof
CA3097569A1 (en) * 2018-04-17 2019-10-24 The Johns Hopkins University Recombinant therapeutic interventions for cancer
CN112746051A (en) * 2020-12-24 2021-05-04 中国人民解放军空军特色医学中心 Recombinant mycobacterium smegmatis strain for expressing methylated HBHA protein, preparation method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US6949345B1 (en) 1996-05-17 2005-09-27 Institut National De La Sante Et De La Recherche Medicale Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin
ES2291810T3 (en) * 1997-04-02 2008-03-01 Statens Serum Institut FRAGMENTS OF NUCLEIC ACID AND FRAGMENTS OF POLPEPTIDES DERIVED FROM M. TUBERCULOSIS.
CA2451045A1 (en) 2001-06-21 2003-09-04 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
FR2832410B1 (en) * 2001-11-19 2004-04-02 Pasteur Institut RECOMBINANT MYCOBACTERIAL ANTIGEN OF HEMAGGLUTININ TYPE OF METHYLATED HEPARIN BINDING, METHODS OF PREPARATION AND IMMUNOGENIC COMPOSITIONS COMPRISING SUCH ANTIGEN
WO2006053871A2 (en) * 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US7829104B2 (en) 2004-12-01 2010-11-09 Aeras Global Tb Vaccine Foundation Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
DK1827504T3 (en) 2004-12-01 2011-08-29 Aeras Global Tb Vaccine Foundation Recombinant BCG strains with increased ability to escape from the endosome
WO2006060332A2 (en) 2004-12-01 2006-06-08 Aeras Global Tb Vaccine Foundation Electroporation of mycobacterium and overexpression of antigens in mycobacteria
GB0500102D0 (en) * 2005-01-05 2005-02-09 Isis Innovation Method for generating a memory t cell response
CN1966689A (en) * 2005-11-15 2007-05-23 华中科技大学 BCG vaccine expression vector and its construction
WO2011013097A2 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
CN101816783B (en) * 2010-04-15 2013-02-06 中国人民解放军第四军医大学 Recombinant Mycobacterium smegmatis vaccine expressing HBHA-IL-12 fusion protein
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
EP2437061A1 (en) * 2010-09-30 2012-04-04 Ikonomopoulos, John Mycobacterial protein detection

Also Published As

Publication number Publication date
US20180305416A1 (en) 2018-10-25
US20150291669A1 (en) 2015-10-15
JP2015515276A (en) 2015-05-28
EP2838990A4 (en) 2016-08-10
WO2013158061A1 (en) 2013-10-24
EP2838990A1 (en) 2015-02-25
US9926346B2 (en) 2018-03-27
CN104508120A (en) 2015-04-08

Similar Documents

Publication Publication Date Title
CY1123515T1 (en) METHODS OF EDUCATING A TAUPATHY
CA3081446A1 (en) Methods and compositions for polypeptide analysis
MX2019006043A (en) Prostate specific membrane antigen binding protein.
PH12018502047A1 (en) Neoantigens and methods of their use
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
MX340498B (en) Heterodimerized polypeptide.
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
CY1117162T1 (en) METHOD OF CONSTRUCTION OF FC-CATHERMAL PARTICULAR PARTS USING ELECTROSTATIC GUIDELINES
PH12018502213A1 (en) Anti-myostatin antibodies and methods of use
CY1123672T1 (en) METHODS OF EDUCATING A TAUPATHY
CR20170282A (en) NEW PEPTIDES AND NEW COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (CHC) AND OTHER TYPES OF CANCER
EA201690529A1 (en) METHODS OF MODIFICATION OF CELL-HOST
ES2662801T3 (en) Vaccines attenuated against Streptoccocus suis and their manufacturing and use procedures
BR112015013525A2 (en) a method for producing a fusion protein as well as a composition comprising a fusion protein
EA201590184A1 (en) VACCINE ON THE BASIS OF MYCOBACTERIAL ANTIGENS
MX2014005108A (en) Polypeptide constructs and uses thereof.
MY171041A (en) Reference picture list construction for video coding
IN2015DN02771A (en)
CL2011003075A1 (en) Precursor protein comprising a repetitive sequence with self-assembling properties that can be cleaved into its components, which comprise a peptide of interest and a self-assembling auxiliary peptide; nucleic acid that encodes it; expression cassette, vector; Method of production; and its use.
MX367423B (en) Binding polypeptides having a mutated scaffold.
WO2013019445A3 (en) Anti-angiogenic peptides and uses thereof
WO2015004458A3 (en) Methods for increasing molecular diversity of polyketides and non-ribosomal proteins
BR112015008036A2 (en) isolated peptide population, method for detecting antibody in a sample, method for diagnosing monocytic and / or granulocytic erlichiosis, and kit
AR090668A1 (en) ANTI-ADAMTS-5 ANTIBODY, DERIVATIVES AND USES OF THE SAME
IN2014DN08675A (en)